• OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • Search in
    • Categories
    • Tags
    • Date within
    • Views
    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Hungarian (Hungary)
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • Self Serve Advertising Portal - Buy Ads Now! No Contracts!
  • How To Self Record An Interview and Presentations
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Advertising Specifications
  • Publisher Calendar

  • Mobile
  • Connect Mobile App

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5616
  • Acute Myelogenous Leukemia 277
  • Bladder 111
  • Bone Metastases 7
  • Brain 90
  • Breast 585
  • Business Management 5
  • Cervical 18
  • Chronic Lymphocytic Leukemia 216
  • Chronic Myelogenous Leukemia 54
  • Colorectal 184
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 182
  • General 350
  • Genitourinary 6
  • Head and Neck 125
  • Help 3
  • Hematologic Malignancies 213
  • Hodgkin Lymphoma 34
  • Imaging 2
  • Immunotherapy 182
  • Kidney 399
  • Liver 41
  • Lung 108
  • Lymphoma 247
  • Melanoma and Skin 111
  • Multiple Myeloma 545
  • Myeloproliferative Disease 41
  • News 152
  • Non-Hodgkin Lymphoma 82
  • Non-Small Cell Lung Cancer 638
  • Other 525
  • Ovarian 67
  • Pancreatic 112
  • Patient Resources 51
  • Pediatric 7
  • Prostate 306
  • Sarcoma 15
  • Sickle Cell 22
  • Small Cell Lung Cancer 83
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 10

  • Install
  • Play a Link
  • About
  • Contact
Pankit Vachhani, MD - Avapritinib versus Placebo in Indolent Systemic Mastocytosis
0:07:55

Pankit Vachhani, MD - Avapritinib versus Placebo in Indolent Systemic Mastocytosis

Interview with Pankit Vachhani, MD Hematology Oncology- UAB Medicine

Timestamps:

0:00:09 What is the objective of this study on indolent systemic mastocytosis (ISM)?
0:00:50 How were patients with ISM randomized in this study, and what were the treatment groups?
0:01:48 What was the primary endpoint measured in this study, and how was it assessed?
0:02:20 What were the secondary endpoints evaluated in this study?
0:03:19 What were the results regarding the mean change in total symptom score (TSS) between the avapritinib and placebo groups?
0:04:17 How did avapritinib treatment impact serum tryptase levels in patients with ISM?
0:05:02 Were there any notable differences in adverse events between the avapritinib and placebo groups?
0:05:59 What were the overall conclusions drawn from this trial regarding the efficacy of avapritinib in treating ISM symptoms and mast-cell burden?
0:06:56 Are there any ongoing trials or research focusing on the long-term safety and efficacy of avapritinib for patients with ISM?

The study aimed to evaluate the efficacy and safety of avapritinib, an inhibitor of the KIT D816V mutation, in treating indolent systemic mastocytosis (ISM). ISM is a clonal mast-cell disease characterized by symptoms caused by the excessive accumulation and activation of mast cells. The trial involved randomized patients with moderate to severe ISM, comparing avapritinib (25 mg once daily) to a placebo, both administered alongside best supportive care. The primary endpoint was the change in the total symptom score (TSS) based on the patient-reported severity of 11 symptoms over a 14-day period. Secondary endpoints included reductions in serum tryptase and blood KIT D816V variant allele fraction, reduction in bone marrow mast cells, and quality of life measures.

Results showed that over 24 weeks, patients treated with avapritinib experienced a significantly greater reduction in TSS (15.6 points decrease) compared to the placebo group (9.2 points decrease). Moreover, a higher proportion of avapritinib-treated patients achieved a ≥50% reduction in serum tryptase levels (54% vs. 0% in the placebo group). Adverse events included edema and elevated alkaline phosphatase, which were more frequent with avapritinib but led to few treatment discontinuations. The trial demonstrated that avapritinib was superior to placebo in reducing symptoms and mast-cell burden in patients with ISM, with ongoing investigations into its long-term safety and efficacy.

41 Views
1 month Ago
Oncology Conferences
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Bone Metastases

Axatilimab in Chronic Graft-Versus-Host Disease AGAVE 201 Results.
0:17:22
Axatilimab in Chronic Graft-Versus-Host Disease AGAVE 201 Results.
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
57 Views
Cancer News
3 weeks Ago
Pankit Vachhani, MD - Avapritinib versus Placebo in Indolent Systemic Mastocytosis
0:07:55
Pankit Vachhani, MD - Avapritinib versus Placebo in Indolent Systemic Mastocytosis
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
41 Views
Oncology Conferences
1 month Ago
FAST-01: 2022 5 Key Takeaways [2022]
FAST-01: 2022 5 Key Takeaways [2022]
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
6 Views
University of Cincinnati
10 months Ago
Podcast Ruben A. Mesa, MD @mpdrc @UTHealthSAMDA #ASCO22 #OncoTwitter @oncoalert Phase III MOMENTUM Study
0:09:16
Podcast Ruben A. Mesa, MD @mpdrc @UTHealthSAMDA #ASCO22 #OncoTwitter @oncoalert Phase III MOMENTUM Study
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
10 Views
Annual Meeting
1 year Ago
Ruben A. Mesa, MD @mpdrc @UTHealthSAMDA #ASCO22 #OncoTwitter @oncoalert Phase III MOMENTUM Study
0:09:16
Ruben A. Mesa, MD @mpdrc @UTHealthSAMDA #ASCO22 #OncoTwitter @oncoalert Phase III MOMENTUM Study
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
26 Views
Annual Meeting
1 year Ago
Kazuhiko Matsuoka, PhD @MedUni_Wien Osteosarcoma (OS) is the most common form of aggressive bone cancer. A MedUni Vienna study, led by geneticist Erwin Wagner, has uncovered new insights ...
0:05:29
Kazuhiko Matsuoka, PhD @MedUni_Wien Osteosarcoma (OS) is the most common form of aggressive bone cancer. A MedUni Vie...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
98 Views
AACR
3 years Ago
If Practitioner Identifies Light-Chain Amyloidosis  Referring to Site Where Trial is Open is a Great Idea
00:00:40
If Practitioner Identifies Light-Chain Amyloidosis Referring to Site Where Trial is Open is a Great Idea
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
267 Views
Annual Meeting
5 years Ago

comments@oncologytube.com Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592 - 1 (951) 944-2173